We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+5.73%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$98.6M
AUM Growth
-$9.18M
Cap. Flow
-$6.23M
Cap. Flow %
-6.32%
Top 10 Hldgs %
86.36%
Holding
30
New
7
Increased
6
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$2.6M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.32M
3
QIPT
Quipt Home Medical
QIPT
+$1.39M
4
ALIM
Alimera Sciences
ALIM
+$1.03M
5
HCSG icon
Healthcare Services Group
HCSG
+$862K

Top Sells

Rank Stock Value
1
ATRS
Antares Pharma, Inc.
ATRS
+$5.52M
2
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$3.48M
3
LNTH icon
Lantheus
LNTH
+$3.24M
4
RAPT
RAPT Therapeutics
RAPT
+$2.42M
5
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$1.89M

Sector Composition

Rank Sector Weight
1 Healthcare 75.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
1
DELISTED
Radius Health, Inc.
RDUS
$18.4M 18.63%
1,771,500
+350,000
+25% +$2.6M
LNTH icon
2
Lantheus
LNTH
$6.59B
$17.7M 17.99%
268,658
-51,342
-16% -$3.24M
ADMA icon
3
ADMA Biologics
ADMA
$2.22B
$12M 12.2%
6,073,598
+250,800
+4% +$493K
IMCR icon
4
Immunocore
IMCR
$1.73B
$10.9M 11.1%
293,385
– –
OPTN
5
DELISTED
OptiNose
OPTN
$7.32M 7.43%
133,333
– –
JSPR icon
6
Jasper Therapeutics
JSPR
$23.6M
$5.48M 5.56%
321,904
– –
XBI icon
7
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$3.71M 3.77%
+50,000
New +$3.75M
TELA icon
8
TELA Bio
TELA
$38.9M
$3.49M 3.54%
498,238
+46,838
+10% +$389K
STLN
9
Starling Oncology, Inc. Common Stock
STLN
$641M
$3.04M 3.08%
600,000
– –
HCSG icon
10
Healthcare Services Group
HCSG
$1.53B
$3.01M 3.06%
173,000
+50,000
+41% +$862K
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.4B
$2.38M 2.42%
+225,000
New +$2.32M
CFMS
12
DELISTED
Conformis, Inc. Common Stock
CFMS
$1.82M 1.85%
206,256
+20,476
+11% +$234K
SNDA icon
13
Sonida Senior Living
SNDA
$1.91B
$1.74M 1.76%
82,832
– –
QIPT
14
DELISTED
Quipt Home Medical
QIPT
$1.4M 1.42%
+302,100
New +$1.39M
RZLT icon
15
Rezolute
RZLT
$452M
$1.29M 1.31%
400,000
+100,000
+33% +$332K
CRBU icon
16
Caribou Biosciences
CRBU
$164M
$1.14M 1.16%
210,695
– –
ALIM
17
DELISTED
Alimera Sciences
ALIM
$1.02M 1.04%
+187,001
New +$1.03M
NYXH
18
Nyxoah
NYXH
$147M
$837K 0.85%
90,997
-71,969
-44% -$1.03M
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.12B
$608K 0.62%
+20,000
New +$605K
RDUS
20
CALL
DELISTED
Radius Health, Inc.
RDUS
$519K 0.53%
+50,000
New +$372K
SNCE
21
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$441K 0.45%
10,976
-47,657
-81% -$3.48M
HZNP
22
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$237K 0.24%
+2,967
New +$281K
NKGNW
23
DELISTED
NKGen Biotech, Inc. Warrants
NKGNW
$5K 0.01%
20,000
– –
SLGCW
24
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$2K ﹤0.01%
2,060
– –
RAPT
25
DELISTED
RAPT Therapeutics
RAPT
– –
-13,750
Closed -$2.42M
1
2

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
RFS
Richardson Financial Services Medway, Massachusetts $160M AUM 16.71% 1-Year Est. Return
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SA
swisspartners Advisors Zurich, Switzerland $159M AUM 36.51% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
CF
CBM Financial Austin, Texas $160M AUM

Velan Capital Investment Management's Q2 2022 Portfolio in Review

As of Q2 2022, Velan Capital Investment Management held 30 positions worth $98.6M, down 8.5% from $108M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Velan Capital Investment Management withdrew a net $6.23M in Q2 2022, closing 6 positions and reducing 3 holdings. Its most notable exit was Antares Pharma, Inc., an estimated $5.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 86% a quarter earlier.

Against the trend, Velan Capital Investment Management opened a new position in BioCryst Pharmaceuticals worth $2.38M.

  • Velan Capital Investment Management's largest Q2 2022 buy was BioCryst Pharmaceuticals: 225,000 shares worth $2.38M.
  • Velan Capital Investment Management added most to Radius Health, Inc. in Q2 2022, an estimated $2.6M increase.
  • Velan Capital Investment Management's biggest Q2 2022 reduction was Science 37 Holdings, Inc. Common Stock, cutting an estimated $3.48M.
  • Velan Capital Investment Management fully exited Antares Pharma, Inc. in Q2 2022, selling an estimated $5.52M.
  • Velan Capital Investment Management's ten largest holdings make up 86% of its $98.6M portfolio in Q2 2022.
  • Velan Capital Investment Management opened 7 new positions and closed 6 in Q2 2022.
  • Velan Capital Investment Management's portfolio value fell 8.5% quarter-over-quarter to $98.6M.

Based on Velan Capital Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.